Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2012
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysisAdrianus J de Langen, Andrew Vincent, Linda M Velasquez, et al.
The Journal of Molecular Diagnostics : JMD|January 29, 2025
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02Zhenhao Qi, Shinya Tokuhiro, Justin I Odegaard, et al.
Nuclear Medicine and Biology|May 22, 2017
Baseline and longitudinal variability of normal tissue uptake values of [18F]-fluorothymidine-PET imagesMatthijs C F Cysouw, Gerbrand M Kramer, Virginie Frings, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2025
Improving the diagnosis of leptomeningeal metastases by molecular profiling of cell-free DNA from cerebrospinal fluidBerit M H van Linder, Dieta Brandsma, Els Verhoeven, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2015
Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PETRamsha Iqbal, Gem M Kramer, Eline E Verwer, et al.
Nature Medicine|August 10, 2021
Limited evolution of the actionable metastatic cancer genome under therapeutic pressureJoris van de Haar, Louisa R Hoes, Paul Roepman, et al.
ERJ Open Research|June 1, 2017
High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodesRieneke van de Ven, Anna-Larissa N Niemeijer, Anita G M Stam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2022
Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLCSophie M Ernst, Joanne M Mankor, Job van Riet, et al.
Pharmaceutical Research|August 17, 2022
Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life SettingRené J Boosman, Merel Jebbink, Wouter B Veldhuis, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Pageof 8